An example of a small, superficial BCC lesion that might be treated with imiquimod. Credit: Journal of Investigative Dermatology
Basal cell carcinoma (BCC) is the most common form of human cancer. With a growing aging population, BCC rates are climbing at an alarming rate, with reported cases rising by as much as 10% per year. A new study examines the effectiveness of imiquimod, a topical skin cream used to treat low-risk BCC lesions, over a five-year period. Imiquimod success rates were sustained for the extended study period and did not promote lesion reoccurrence.
Currently, the gold standard of treatment for BCC is excisional or Mohs surgery, both of which require a dermatologist or plastic surgeon...
Read More
Recent Comments